Complete dosing information for OCRELIZUMAB AND HYALURONIDASE
Medical guidance required: Dosing information here is for educational purposes. Your healthcare provider will determine the appropriate dose based on your specific condition, kidney function, other medications, and medical history. Never adjust your dose without consulting your doctor or pharmacist.
2 DOSAGE AND ADMINISTRATION OCREVUS ZUNOVO should be administered by a healthcare professional ( 2.1 ) For subcutaneous use in the abdomen only ( 2.1 ) OCREVUS ZUNOVO has different dosage and administration instructions than intravenous ocrelizumab ( 2.1 ) Before initiating OCREVUS ZUNOVO, screen for Hepatitis B virus and obtain serum quantitative immunoglobulins, aminotransferases, alkaline phosphatase, and bilirubin ( 2.2 ) Pre-medicate orally with dexamethasone (or an equivalent corticosteroid) and an antihistamine (e.g., desloratadine) at least 30 minutes prior to each injection ( 2.3 ) Administer 23 mL of OCREVUS ZUNOVO (920 mg ocrelizumab and 23,000 units hyaluronidase) subcutaneously in the abdomen over approximately 10 minutes every 6 months ( 2.4 ) Monitor patients closely during all injections, for at least one hour after the initial injection, and for at least 15 minutes after subsequent injections ( 2.4 ) 2.1 Important Administration Information OCREVUS ZUNOVO is for subcut